The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

Shionogi has prior experience in Covid-19 drug development. In 2024, the company’s antiviral drug Xocova (ensitrelvir) received full approval in Japan, but the Phase III SCORPIO-HR trial ...

The remaining Xocova tablets produced by Shionogi & Co., Lagevrio capsules made by Merck & Co. and Paxlovid pills manufactured by Pfizer Inc., estimated to be worth 300 billion yen ($1.93 billion ...

Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based pharmaceutical company with more than 5,500 employees and operations around the globe, including offices in the US ...

Japanese pharmaceutical group, Shionogi &amp, Co is entering into an agreement with ViiV Healthcare, substantially revising their integrase inhibitor relationship. ViiV Healthcare was established ...

Shionogi & Co.'s oral COVID-19 pill in development will likely not be recommended for pregnant women due to abnormalities detected in animal testing, the company said April 12. The Osaka-based ...